This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
ASX Market Open: Aussie market to leap on best ‘Trump trade’ bump since election day | November 22, 2024
The ASX 200 is tipped to rise as much as 1% at open today after Wall Street enjoyed another major “Trump trade” surge
- Isaac McIntyre
- 2 mins
- 22 November 2024 08:44 (AEDT)
ASX Market Close: Bourse closes flat after Min Res AGM | November 21, 2024
Besieged Mineral Resources (ASX:MIN) Managing Director Chris Ellison told its AGM he deeply regrets his dodgy…
- Sean Boss
- 2 mins
- 21 November 2024 16:49 (AEDT)
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech
Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision…
- Caroline Smith
- 1 min
- 21 November 2024 16:45 (AEDT)
Quiet day one for Symal Group but slow ASX start no real surprise
Civil construction company Symal Group (ASX:SYL) had a relatively quiet first day after
- Isaac McIntyre
- 3 mins
- 21 November 2024 16:05 (AEDT)